New Delhi, Jan. 31 -- The Supreme Court has held that administering stem cell therapy for the treatment of Autism Spectrum Disorder (ASD) outside an approved and monitored clinical trial is unethical and amounts to medical malpractice.
The Court clarified that such therapy is permissible only within the framework of duly approved clinical trials aimed at advancing scientific knowledge.
A Bench comprising Justice J B Pardiwala and Justice R Mahadevan delivered the ruling in Yash Charitable Trust v. union of India, observing that stem cell therapy for autism is not recognised as a sound or relevant medical practice due to the absence of credible scientific support and empirical evidence regarding its safety and efficacy.
"Therefore, every ...